Professor Steve Jackson earns KBE for services to innovation and research
CAMBRIDGE, UK – 17 June 2023 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), sends its congratulations to the company’s founder, Professor Steve Jackson, who has been made a Knight Bachelor as part of His Majesty The King’s Birthday Honours List.
Buckingham Palace confirmed the award was for services to innovation and research when the full list was announced on 17 June 2023.
Professor Jackson was appointed Frederick James Quick Professor of Biology at the University of Cambridge in 1995. He founded Mission Therapeutics in 2011 in order to advance and explore new therapeutic opportunities through his research in protein ubiquitylation and deubiquitylation. He has served as Chairman of the Scientific Advisory Board since the Company’s founding.
Professor Jackson also serves as Senior Group leader at Cancer Research UK Cambridge Institute, having previously been Head of Laboratories at the University’s Gurdon Institute. His team was responsible for the discovery of the mechanism that led to the creation of Olaparib, the world’s first marketed DNA-repair enzyme inhibitor, which has now been administered to over 60,000 patients globally.
Anker Lundemose, CEO of Mission Therapeutics, said: “The team at Mission are delighted for Steve and wish him many congratulations. His pioneering research and discoveries in the DUB field are the inspiration for Mission. His continued guidance on the Company’s development has been invaluable. The team at Mission are very proud of his achievements and this recognition in the Birthday Honours list is richly deserved.”
– ENDS –
FOR MORE INFORMATION PLEASE CONTACT:
|Mission Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel: +44 (0)1223 607 340
Melanie Toyne-Sewell / Adam Loudon
Tel: +44 (0) 20 7457 2013
NOTES TO EDITORS:
About Mission Therapeutics
Mission Therapeutics is a clinical-stage drug development company targeting the ubiquitin pathway for the treatment of kidney disease, heart disease and neurodegenerative disease. The Company has built a leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.
Mission has strong links with key academic and research centers, including Prof. Steve Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company also has secured major industry partnerships, including its collaboration with AbbVie in November 2018, for the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease. The Company is managed by a team with broad international, commercial and clinical-science experience.
To date the Company has received $112 million in funding and its investors comprise blue chip institutional and corporate investors including: Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group and Rosetta Capital. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.